TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00849745

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative allogeneic stem cell transplant
Description: Prior to receiving Campath-1H, patients will be premedicated with Benadryl 50 mg IV or PO, and acetaminophen 650 mg orally. Hydrocortisone 100 mg IV is given on the first day of Campath. The preparative regimen will begin on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours. The mixed dosage of chemotherapy may be rounded off to within +/- 5% of the calculated dose, and doses of fludarabine and cyclophosphamide will be based on adjusted ideal body weight. IV hydration and diuretics will be used to maintain adequate urine output during and after administration of cyclophosphamide.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative allogeneic stem cell transplant
Description: Prior to receiving Campath-1H, patients will be premedicated with Benadryl 50 mg IV or PO, and acetaminophen 650 mg orally. Hydrocortisone 100 mg IV is given on the first day of Campath. The preparative regimen will begin on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours. The mixed dosage of chemotherapy may be rounded off to within +/- 5% of the calculated dose, and doses of fludarabine and cyclophosphamide will be based on adjusted ideal body weight. IV hydration and diuretics will be used to maintain adequate urine output during and after administration of cyclophosphamide.
Study: NCT03879083

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Addition of palatal rugae to the complete denture surface
Description: The addition and reproduction of the patient's own palatal rugae to the complete maxillary denture palatal surface.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The removal of the palatal rugae from the complete denture surface
Description: The removal of the palatal rugae from the complete maxillary denture palatal surface to become a smooth surface
Study: NCT02115178

Intervention type: OTHER
Intervention: Lithotomy or Prone position
Description: The surgery, haemodynamic measurements will be performed in Lithotomy or Prone position
Study: NCT04156178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD20-CD19 cCAR T cells
Description: CD20-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
Study: NCT00899379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate
Description: Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate
Description: Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate
Description: Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate
Description: Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate
Description: Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to Rizatriptan, Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to Rizatriptan, Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to Rizatriptan, Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to Rizatriptan, Oral Tablet
Study: NCT04151706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD8+ Memory T Cell Infusion
Description: Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 5 mg/kg/day: IV for 2 consecutive days (days -6 to -5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2/day: IV for 5 consecutive days (days -6 to -2)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperfractionated TBI
Description: Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg
Study: NCT01204593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLULISINE
Description: Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: three times a day, preferably just before the meal
Study: NCT02084355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral oxycodone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral oxycodone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral hydromorphone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral hydromorphone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl patch
Study: NCT02166047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Vesatolimod tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Vesatolimod tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Vesatolimod tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Vesatolimod tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Vesatolimod tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Vesatolimod tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Vesatolimod tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Vesatolimod tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Vesatolimod tablet administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match vesatolimod tablet administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match vesatolimod tablet administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match vesatolimod tablet administered orally
Study: NCT03134976

Intervention type: DRUG
Intervention: Levothyroxine
Description: Immediately post-operatively, all patients undergoing laryngectomy will be started on established weight-based dosing of levothyroxine administered intravenously due to the variable enteral absorption in post-operative patients including those on continuous tube feed regimens. Standard enteral dose is 1.6 mcg/kg/day. Eighty percent of this dose (1.3 mcg/kg/day) will be given IV to account for the increased bioavailability of IV levothyroxine compared to enteral levothyroxine. The maximum dose will be 200 mcg/day. Patients previously on levothyroxine at doses lower than the above dose will changed to the aforementioned standard dose. Patients on higher doses of levothyroxine pre-operatively will be maintained on on their current dosing.
Study: NCT01730742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroeconomics task
Description: After a night of wakefulness, participants performed the neuroeconomics task (shopping food items in a mock supermarket scenario).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroeconomics task
Description: After a night of wakefulness, participants performed the neuroeconomics task (shopping food items in a mock supermarket scenario).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portion Size Task
Description: Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portion Size Task
Description: Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: After a night of wakefulness, a blood sample was taken to assess the level and efficacy of circulating neutrophils, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as oxytocin and ghrelin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: After a night of wakefulness, a blood sample was taken to assess the level and efficacy of circulating neutrophils, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as oxytocin and ghrelin
Study: NCT03470103

Intervention type: DRUG
Intervention: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Description: Use of intravitreal aflibercept in routine clinical practice in Latin America

Intervention type: DRUG
Intervention: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Description: Use of intravitreal aflibercept in routine clinical practice in Latin America

Intervention type: DRUG
Intervention: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Description: Use of intravitreal aflibercept in routine clinical practice in Latin America
Study: NCT03050047

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-100
Description: Anti-PD1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-100
Description: Anti-PD1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-100
Description: Anti-PD1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-100
Description: Anti-PD1 monoclonal antibody
Study: NCT04996511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseOn
Description: Postoperative HRV measurement
Study: NCT02673268

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mastectomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Da Vinci Robot Xi
Study: NCT02553707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
Study: NCT01210144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal -f® [r-hFSH]
Description: On Day 2 of the menstrual cycle, a pre-defined fixed dose of 150 International Units (IU) per day of recombinant human follicle stimulating hormone (r-hFSH) will be administered until follicles are recruited and developed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal -f® [r-hFSH]
Description: On Day 2 of the menstrual cycle, a pre-defined fixed dose of 150 International Units (IU) per day of recombinant human follicle stimulating hormone (r-hFSH) will be administered until follicles are recruited and developed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovitrelle® [r-hCG alfa]
Description: Ovulation triggering will be performed using a single injection of 250 microgram (mcg) recombinant human chorionic gonadotropin (r-hCG) alfa as soon as follicles satisfy the criteria for follicular development, that is at least 3 follicles greater than (\>) 16 millimeter (mm), and with estradiol (E2) \> 1 microgram per liter (mcg/L) if gonadotropin releasing hormone (GnRH) agonist will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovitrelle® [r-hCG alfa]
Description: Ovulation triggering will be performed using a single injection of 250 microgram (mcg) recombinant human chorionic gonadotropin (r-hCG) alfa as soon as follicles satisfy the criteria for follicular development, that is at least 3 follicles greater than (\>) 16 millimeter (mm), and with estradiol (E2) \> 1 microgram per liter (mcg/L) if gonadotropin releasing hormone (GnRH) agonist will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) Agonist
Description: To prevent premature ovulation in participants undergoing a controlled ovarian stimulation (COS), 0.1 milligram (mg) GnRH agonist daily will be given after endometrial biopsy, 7 days after the peak day of luteinizing hormone (Day LH + 7) as per summary of product characteristics (SmPC), in long agonist protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) Antagonist
Description: To prevent premature ovulation in participants undergoing a COS, 0.25 mg GnRH antagonist daily will be given from Day 6 of Gonal-f® stimulation treatment as per SmPC, in multi-dose antagonist protocol.
Study: NCT02456038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asfotase Alfa (ALXN1215)
Study: NCT03470103

Intervention type: DRUG
Intervention: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Description: Use of intravitreal aflibercept in routine clinical practice in Latin America
Study: NCT01800019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Study: NCT02986659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study: NCT01800019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Tailored Quit Smoking Counseling
Description: A cognitive behavioral therapy (CBT) oriented smoking cessation program tailored to HIV positive individuals.~People Living with HIV/AIDS (PHA) tailored Canadian HIV Quit Smoking Counseling Intervention. It consists of face-to-face counseling sessions with a trained smoking cessation counsellor at randomization, on the identified quit date, and then at weeks 4, 8, 12, and 24.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Tailored Quit Smoking Counseling
Description: A cognitive behavioral therapy (CBT) oriented smoking cessation program tailored to HIV positive individuals.~People Living with HIV/AIDS (PHA) tailored Canadian HIV Quit Smoking Counseling Intervention. It consists of face-to-face counseling sessions with a trained smoking cessation counsellor at randomization, on the identified quit date, and then at weeks 4, 8, 12, and 24.
Study: NCT04529850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: GC4419
Description: GC4419 60 Minute Infusion
Study: NCT02986659

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04529850

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Description: 2.0 to 2.2 Gy daily over 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100mg/m2 once every 3 weeks or 40mg/m2 once weekly for 6-7 doses
Study: NCT03339336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT04977492

Intervention type: PROCEDURE
Intervention: extracapsular release of lateral retinaculum
Description: A new kind of surgery which releases the lateral retinaculum from outside the knee capsular, maintaining the structure of the knee capsular.
Study: NCT03161249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: The experimental group receiving mobile treatment: treatment as usual plus a psychotherapy intervention by the telephone app (a total of 5 modules of psychotherapy: psychoeducation plus mindfulness plus alerts plus social wall plus problems solving)

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Group that does not receive any treatment added to its usual treatment
Study: NCT03026933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KI1107 4 Capsules, QD
Description: KI1107 4 Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin Calcium 20 MG, QD
Description: Rosuvastatin Calcium 20mg, QD
Study: NCT01702532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Comparison of different dosage forms of nicotine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Comparison of different dosage forms of nicotine
Study: NCT04012281

Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: PCI was performed using 2nd generation DES
Study: NCT02271724

Intervention type: PROCEDURE
Intervention: Lumbar puncture
Description: Lumbar puncture for spinal fluid

Intervention type: PROCEDURE
Intervention: Lumbar puncture
Description: Lumbar puncture for spinal fluid

Intervention type: PROCEDURE
Intervention: Lumbar puncture
Description: Lumbar puncture for spinal fluid

Intervention type: PROCEDURE
Intervention: Lumbar puncture
Description: Lumbar puncture for spinal fluid

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood sample

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood sample

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood sample

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood sample
Study: NCT01451242

Intervention type: OTHER
Intervention: no intervention is made
Description: no intervention is made
Study: NCT03448939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S5G4T-1
Description: Once a day topical cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S5G4T-2
Description: Once a day topical cream
Study: NCT03093051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unpinning Termination therapy
Description: Electrotherapy comprised of standard biphasic and monophasic pacing pulses
Study: NCT04134520

Intervention type: DEVICE
Intervention: ProLung System
Description: Non-invasive bioconductance measurements

Intervention type: DEVICE
Intervention: ProLung System
Description: Non-invasive bioconductance measurements
Study: NCT01205074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 13C Methacetin Breath Test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 13C Methacetin Breath Test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 13C Methacetin Breath Test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 13C Methacetin Breath Test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 13C Methacetin Breath Test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 13C Methacetin Breath Test

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape fruit juice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non selective beta blocker - Propranolol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ethanol
Study: NCT05136534

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: subarachnoid anesthesia with 2% hyperbaric pilicaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia
Description: (Mepivacaine 2%) performed by the surgeon before skin incision
Study: NCT01618019

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: 5 capsules/day of either n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
Study: NCT03668730

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: Patients undergo low-dose OR standard dose IMRT based on their radiographic response to induction chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: Patients undergo low-dose OR standard dose IMRT based on their radiographic response to induction chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome
Description: Patients receive Paclitaxel liposome by 135mg/m2 with a total of two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome
Description: Patients receive Paclitaxel liposome by 135mg/m2 with a total of two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients receive Cisplatin by 25mg/m2 on day1-day3 with a total of two cycles as induction chemotherapy ; patients receive cisplatin by 100mg/m2 with a total of three cycles as concurrent chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients receive Cisplatin by 25mg/m2 on day1-day3 with a total of two cycles as induction chemotherapy ; patients receive cisplatin by 100mg/m2 with a total of three cycles as concurrent chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Patients receive 5-Fluorouracil by 3750mg/m2 civ120h with a total of three cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Patients receive 5-Fluorouracil by 3750mg/m2 civ120h with a total of three cycles.
Study: NCT00422799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Once weekly for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenously once a week for the first and fourth weeks of a cycle